Literature DB >> 31062182

Pain in Cancer Survivors: How to Manage.

Judith A Paice1.   

Abstract

OPINION STATEMENT: Managing pain in cancer survivors requires that oncologists understand the common painful syndromes that can occur from treatment or disease. Assessment no longer singularly focuses on pain characteristics (e.g., intensity, quality, location), now incorporating a strong focus on functional impairment and potential improvement that might occur with adequate treatment. Improvement in function is now the goal used to measure success. In addition, assessment must incorporate risk factors that might predispose patients to substance use disorder so that interventions can be implemented to mitigate this risk. Universal precautions are measures that help assess and ensure adherence to the treatment plan and may include the use of agreements, urine toxicology, and review of dispensing information derived from state prescription drug monitoring program (PDMP). These are generally obtained annually for all individuals, although some states have instituted mandatory review of the PDMP whenever prescribing an opioid. For patients at moderate to high risk for misuse of opioids, where opioids are warranted for the treatment of their pain syndrome, universal precautions are instituted more frequently. Other measures may include prescribing a 1- to 2-week supply of medications if compulsive use leads the patient to running out of drug early, and in some cases, family members may be employed to dispense daily allotments of the medication. When opioids are no longer indicated, gradual tapering of the drug by approximately 10% per month is generally sufficient to prevent withdrawal symptoms and ensure patient acceptance.

Entities:  

Keywords:  Cancer; Chemotherapy; Opioids; Pain; Radiotherapy; Surgery

Mesh:

Substances:

Year:  2019        PMID: 31062182     DOI: 10.1007/s11864-019-0647-0

Source DB:  PubMed          Journal:  Curr Treat Options Oncol        ISSN: 1534-6277


  41 in total

1.  Can prescription drug monitoring programs help limit opioid abuse?

Authors:  Hallam M Gugelmann; Jeanmarie Perrone
Journal:  JAMA       Date:  2011-11-23       Impact factor: 56.272

2.  The Danish National Cohort Study (DANCOS).

Authors:  Michael Davidsen; Mette Kjøller; Karin Helweg-Larsen
Journal:  Scand J Public Health       Date:  2011-07       Impact factor: 3.021

3.  Pain in long-term breast cancer survivors: frequency, severity, and impact.

Authors:  Mark P Jensen; Hao-Yuan Chang; Yeur-Hur Lai; Karen L Syrjala; Jesse R Fann; Julie R Gralow
Journal:  Pain Med       Date:  2010-06-08       Impact factor: 3.750

Review 4.  A comprehensive review of opioid-induced hyperalgesia.

Authors:  Marion Lee; Sanford M Silverman; Hans Hansen; Vikram B Patel; Laxmaiah Manchikanti
Journal:  Pain Physician       Date:  2011 Mar-Apr       Impact factor: 4.965

Review 5.  Urine drug testing in chronic pain.

Authors:  Paul J Christo; Laxmaiah Manchikanti; Xiulu Ruan; Michael Bottros; Hans Hansen; Daneshvari R Solanki; Arthur E Jordan; James Colson
Journal:  Pain Physician       Date:  2011 Mar-Apr       Impact factor: 4.965

Review 6.  Prevalence of pain in patients with cancer: a systematic review of the past 40 years.

Authors:  M H J van den Beuken-van Everdingen; J M de Rijke; A G Kessels; H C Schouten; M van Kleef; J Patijn
Journal:  Ann Oncol       Date:  2007-03-12       Impact factor: 32.976

7.  Cancer-related chronic pain: examining quality of life in diverse cancer survivors.

Authors:  Carmen R Green; Tamera Hart-Johnson; Deena R Loeffler
Journal:  Cancer       Date:  2010-11-18       Impact factor: 6.860

Review 8.  Recommendations for urine drug monitoring as a component of opioid therapy in the treatment of chronic pain.

Authors:  John F Peppin; Steven D Passik; Joseph E Couto; Perry G Fine; Paul J Christo; Charles Argoff; Gerald M Aronoff; Daniel Bennett; Martin D Cheatle; Kieran A Slevin; Neil I Goldfarb
Journal:  Pain Med       Date:  2012-06-13       Impact factor: 3.750

Review 9.  Radiation-induced neuropathy in cancer survivors.

Authors:  Sylvie Delanian; Jean-Louis Lefaix; Pierre-François Pradat
Journal:  Radiother Oncol       Date:  2012-12       Impact factor: 6.280

Review 10.  Troublesome symptoms in cancer survivors: fatigue, insomnia, neuropathy, and pain.

Authors:  Deirdre R Pachman; Debra L Barton; Keith M Swetz; Charles L Loprinzi
Journal:  J Clin Oncol       Date:  2012-09-24       Impact factor: 44.544

View more
  7 in total

Review 1.  Updates in the Treatment of Chemotherapy-Induced Peripheral Neuropathy.

Authors:  Jessica N Mezzanotte; Michael Grimm; Namrata V Shinde; Timiya Nolan; Lise Worthen-Chaudhari; Nicole O Williams; Maryam B Lustberg
Journal:  Curr Treat Options Oncol       Date:  2022-02-15

2.  Approaches to opioid prescribing in cancer survivors: Lessons learned from the general literature.

Authors:  Katie Fitzgerald Jones; Jessica S Merlin
Journal:  Cancer       Date:  2021-10-11       Impact factor: 6.860

Review 3.  Cancer pain during an epidemic and a pandemic.

Authors:  Judith A Paice
Journal:  Curr Opin Support Palliat Care       Date:  2022-06-01       Impact factor: 2.265

4.  Modular transitional nursing intervention improves pain-related self-management for cancer patients: Study protocol for a randomized controlled trial.

Authors:  Beibei Miao; Yali Sun; Ling Gong; Wei Liu
Journal:  Medicine (Baltimore)       Date:  2020-12-18       Impact factor: 1.817

Review 5.  Pharmacologic Management of Persistent Pain in Cancer Survivors.

Authors:  Paul Glare; Karin Aubrey; Amitabh Gulati; Yi Ching Lee; Natalie Moryl; Sarah Overton
Journal:  Drugs       Date:  2022-02-17       Impact factor: 9.546

6.  The Role of Vascular-Immune Interactions in Modulating Chemotherapy Induced Neuropathic Pain.

Authors:  Tameille Valentine; Lydia Hardowar; Jasmine Elphick-Ross; Richard P Hulse; Mark Paul-Clark
Journal:  Front Pharmacol       Date:  2022-06-22       Impact factor: 5.988

7.  Variations in pain prevalence, severity, and analgesic use by duration of survivorship: a cross-sectional study of 505 post-treatment head and neck cancer survivors.

Authors:  Jenny L Ren; Raniv D Rojo; Joy Vanessa D Perez; Sai-Ching J Yeung; Ehab Y Hanna; Cielito C Reyes-Gibby
Journal:  BMC Cancer       Date:  2021-12-06       Impact factor: 4.430

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.